1.40
-0.02(-1.41%)
Currency In USD
| Previous Close | 1.42 |
| Open | 1.42 |
| Day High | 1.43 |
| Day Low | 1.38 |
| 52-Week High | 3.87 |
| 52-Week Low | 0.39 |
| Volume | 1.02M |
| Average Volume | 19.12M |
| Market Cap | 102.19M |
| PE | -1.82 |
| EPS | -0.77 |
| Moving Average 50 Days | 1.64 |
| Moving Average 200 Days | 0.97 |
| Change | -0.02 |
If you invested $1000 in Rani Therapeutics Holdings, Inc. (RANI) since IPO date, it would be worth $127.27 as of January 14, 2026 at a share price of $1.4. Whereas If you bought $1000 worth of Rani Therapeutics Holdings, Inc. (RANI) shares 3 years ago, it would be worth $225.44 as of January 14, 2026 at a share price of $1.4.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen
GlobeNewswire Inc.
Jan 08, 2026 12:00 PM GMT
- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (
Rani Therapeutics to Participate in the Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 24, 2025 9:05 PM GMT
SAN JOSE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that
Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025
GlobeNewswire Inc.
Oct 30, 2025 12:00 PM GMT
SAN JOSE, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that